Unknown

Dataset Information

0

Rational Design and Synthesis of D-galactosyl Lysophospholipids as Selective Substrates and non-ATP-competitive Inhibitors of Phosphatidylinositol Phosphate Kinases.


ABSTRACT: Phosphatidylinositol phosphate kinases (PIPKs) produce lipid signaling molecules and have been attracting increasing attention as drug targets for cancer, neurodegenerative diseases, and viral infection. Given the potential cross-inhibition of kinases and other ATP-utilizing enzymes by ATP-competitive inhibitors, targeting the unique lipid substrate binding site represents a superior strategy for PIPK inhibition. Here, by taking advantage of the nearly identical stereochemistry between myo-inositol and D-galactose, we designed and synthesized a panel of D-galactosyl lysophospholipids, one of which was found to be a selective substrate of phosphatidylinositol 4-phosphate 5-kinase. Derivatization of this compound led to the discovery of a human PIKfyve inhibitor with an apparent IC50 of 6.2 μM, which significantly potentiated the inhibitory effect of Apilimod, an ATP-competitive PIKfyve inhibitor under clinical trials against SARS-CoV-2 infection and amyotrophic lateral sclerosis. Our results provide the proof of concept that D-galactose-based phosphoinositide mimetics can be developed into artificial substrates and new inhibitors of PIPKs.

SUBMITTER: Sun M 

PROVIDER: S-EPMC10099810 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rational Design and Synthesis of D-galactosyl Lysophospholipids as Selective Substrates and non-ATP-competitive Inhibitors of Phosphatidylinositol Phosphate Kinases.

Sun Mengxia M   Zhang Chi C   Sui Dexin D   Yang Canchai C   Pyeon Dohun D   Huang Xuefei X   Hu Jian J  

Chemistry (Weinheim an der Bergstrasse, Germany) 20221124 2


Phosphatidylinositol phosphate kinases (PIPKs) produce lipid signaling molecules and have been attracting increasing attention as drug targets for cancer, neurodegenerative diseases, and viral infection. Given the potential cross-inhibition of kinases and other ATP-utilizing enzymes by ATP-competitive inhibitors, targeting the unique lipid substrate binding site represents a superior strategy for PIPK inhibition. Here, by taking advantage of the nearly identical stereochemistry between myo-inosi  ...[more]

Similar Datasets

| S-EPMC9097471 | biostudies-literature
| S-EPMC4978281 | biostudies-literature
| S-EPMC4123212 | biostudies-literature
| S-EPMC5156328 | biostudies-literature
| S-EPMC2806594 | biostudies-literature
| S-EPMC4974024 | biostudies-literature
| S-EPMC5991623 | biostudies-literature
| S-EPMC4016787 | biostudies-literature
| S-EPMC5751415 | biostudies-literature
| S-EPMC4466670 | biostudies-literature